Vericiguat tablet

DRUG2 trials

Sponsors

Merck Sharp & Dohme LLC, Khawaja Danish Ali

Conditions

Decompensated Heart FailureHeart FailureLeft Ventricular Systolic Dysfunction

Phase 1

Vericiguat in Decompensated Cardiac Failure: Clinical Insights on Addition to Guidelines Derived Medical Therapy-VERCIG Trial

RecruitingNCT07444398

Khawaja Danish AliDecompensated Heart Failure

Start: 2026-01-01End: 2026-03-31Target: 130Updated: 2026-03-02

Phase 2

Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)

RecruitingNCT05714085

Merck Sharp & Dohme LLCHeart Failure, Left Ventricular Systolic Dysfunction

Start: 2023-05-31End: 2032-04-15Target: 342Updated: 2026-03-31

Related Papers

Clinical Pharmacokinetic and Pharmacodynamic Profile of Vericiguat.

2024-06-256 citations